modified T cells

BIOLOGICAL2 trials

Sponsors

Memorial Sloan Kettering Cancer Center

Conditions

LeukemiaRelapsed B-Cell Acute Lymphoblastic Leukemia

Phase 1

Consolidation Therapy With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 in Patients With Chronic Lymphocytic Leukemia Following Upfront Chemotherapy With Pentostatin, Cyclophosphamide and Rituximab

CompletedNCT01416974

Memorial Sloan Kettering Cancer CenterLeukemia

Start: 2011-08-22End: 2019-01-07Updated: 2019-01-11

T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia

Active, not recruitingNCT01860937

Memorial Sloan Kettering Cancer CenterRelapsed B-Cell Acute Lymphoblastic Leukemia

Start: 2013-05-01End: 2027-05-01Updated: 2026-06-08

Related Papers

CAR HEMATOTOX independently predicts outcomes after CD19 CAR-T therapy for acute lymphoblastic leukemia.

2026-01-011 citations

Impact of Bridging Chemotherapy on Clinical Outcomes of CD19-Specific CAR T Cell Therapy in Children/Young Adults with Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia.

2021-11-2833 citations

Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL

Blood2019-10-18271 citations

Updated results: phase I trial of autologous CD19-targeted CAR T cells in patients with residual CLL following initial purine analog-based therapy.

Journal of Clinical Oncology2016-05-206 citations

Multi-Center Clinical Trial of CAR T Cells in Pediatric/Young Adult Patients with Relapsed B-Cell ALL

Blood2015-12-0310 citations

Chimeric Antigen Receptor (CAR) T Cells Targeting the CD19 Antigen for the Treatment of Pediatric Relapsed B Cell ALL

Blood2014-12-063 citations

Phase I trial of autologous CD19-targeted CAR-modified t cells as consolidation after purine analog-based first-line therapy in patients with previously untreated CLL.

Journal of Clinical Oncology2014-05-206 citations